Date: Wednesday, November 20th, 2019
Stock(s) mentioned: JNJ
Source: TheStreet (https://www.thestreet.com)
Summary: Johnson & Johnson gets a healthy financial checkup and prescription from Cantor Fitzgerald, with an initial overweight recommendation and one-year price target roughly 19% higher than current levels.
Full article address: https://www.thestreet.com/investing/stocks/johnson-johnson-gets-overweight-rating-from-cantor-fitzgerald-15174469
Related News:
$JNJ $BA $FB: J&J CEO spurns US congressional hearing on carcinogens in talc products
$MRK $ARQL $SNY $THOR $XBIT $JNJ: Drugmakers have spent a record $342 billion on M&A in 2019
$BLUE $JNJ $BMY $IBB $SPX: Bluebird Bio Gains on Promising Cancer-Drug Data
$PFE $MRK $JNJ $AMGN: Amgen Gets FDA Approval for J&J/Merck’s Remicade Biosimilar
$GSK $PFE $JNJ $GILD: Glaxo Files NDA for Fostemsavir for Heavily Pre-Treated HIV
$XLV $JNJ $PFE $UNH: This ETF should tell you if Elizabeth Warren has a chance in 2020 or not
$JNJ $ABBV $MRK $RHHBY: J&J Stock Witnesses Volatility in ’19: What to Expect in 2020
$JNJ $SPX: J&J Says FDA Was Wrong About Asbestos In Baby Powder
$AZN $JNJ $AGN $ALKS: AstraZeneca Sells Schizophrenia Drug Rights in US and Canada
$JNJ $ENDP $TEVA $MNK: J&J’s (JNJ) New Tests Reveal No Asbestos in Baby Powders
Latest News:
$NTIC: Will Northern Technologies International Continue to Surge Higher?
$DJI $SPX $IXIC $AZO $HDS: US futures point to slightly higher open
$JD $MSFT: Nintendo shares hit near 19-month high as Switch goes on sale in China
$DJIA: Capitol Report: U.S.-China trade talks going in ‘good direction,’ Kushner says
$MA $V $AXP: Someone Is Betting Big That Mastercard Stock Won’t Tumble. How You Can Too.
$JNJ $BA $FB: J&J CEO spurns US congressional hearing on carcinogens in talc products
$T: AT&T shares can go ‘much, much higher’ from here if management can deliver, Jim Cramer says
